tradingkey.logo

DaVita Inc

DVA
查看詳細走勢圖
153.954USD
+1.744+1.15%
交易中 美東報價延遲15分鐘
28.94B總市值
15.30本益比TTM

DaVita Inc

153.954
+1.744+1.15%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.15%

5天

+2.65%

1月

+2.02%

6月

+15.22%

今年開始到現在

+35.51%

1年

+2.36%

查看詳細走勢圖

TradingKey DaVita Inc股票評分

單位: USD 更新時間: 2026-03-24

操作建議

DaVita Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療服務供應商行業排名31/75位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為151.51。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

DaVita Inc評分

相關信息

行業排名
31 / 75
全市場排名
176 / 4547
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

DaVita Inc亮點

亮點風險
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
估值合理
公司最新PE估值15.24,處於3年歷史合理位
機構加倉
最新機構持股36.29M股,環比增加0.04%
路易斯·摩爾·貝肯持倉
明星投資者路易斯·摩爾·貝肯持倉,最新持倉56.35K股

分析師目標

基於 10 分析師
持有
評級
151.514
目標均價
+1.48%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

DaVita Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

DaVita Inc簡介

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
公司代碼DVA
公司DaVita Inc
CEORodriguez (Javier J)
網址https://www.davita.com/
KeyAI